MAM
GNMX

Meeder Asset Management’s Aevi Genomic Medicine Inc GNMX Stock Holding History

Meeder Asset Management’s Portfolio GNMX Stock Details GNMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-605
Closed – – 1956
2018
Q4 		$0 Sell
605
-4,800
-89% -$5.36K ﹤0.01% 1872
2018
Q3 		$7K Buy
5,405
+3,067
+131% +$3.43K ﹤0.01% 1269
2018
Q2 		$2.6K Sell
2,338
-233
-9% -$354 ﹤0.01% 1384
2018
Q1 		$5K Sell
2,571
-853
-25% -$1.6K ﹤0.01% 1256
2017
Q4 		$4K Buy
3,424
+568
+20% +$775 ﹤0.01% 1400
2017
Q3 		$4K Buy
2,856
+1,415
+98% +$1.81K ﹤0.01% 1347
2017
Q2 		$2K Buy
1,441
+859
+148% +$1.24K ﹤0.01% 1466
2017
Q1 		$1K Sell
582
-1,863
-76% -$8.43K ﹤0.01% 1604
2016
Q4 		$13K Buy
+2,445
New +$12.9K ﹤0.01% 717

Other funds holding GNMX

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Meeder Asset Management's GNMX Position: Q1 2019 in Review

Meeder Asset Management sold out of Aevi Genomic Medicine Inc (GNMX) in Q1 2019, closing a stake of 605 shares.

Meeder Asset Management first reported a position in GNMX in Q4 2016 and held it in 9 quarters. The position peaked at $13K in Q4 2016. 28 funds tracked by Wall St. Rank hold GNMX as of Q1 2019.

  • Meeder Asset Management reported no remaining Aevi Genomic Medicine Inc position as of Q1 2019 after selling out during the quarter.
  • Meeder Asset Management sold 605 Aevi Genomic Medicine Inc shares in Q1 2019.
  • Meeder Asset Management first reported a position in Aevi Genomic Medicine Inc in Q4 2016 and held it in 9 quarters.
  • Meeder Asset Management's Aevi Genomic Medicine Inc position peaked at $13K in Q4 2016.
  • 28 funds tracked by Wall St. Rank held Aevi Genomic Medicine Inc as of Q1 2019.

Based on Meeder Asset Management's 13F filing for Q1 2019, filed 16 Apr 2019.